Clinical Trial Update: Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial update on adalimumab for induction and maintenance of clinical remission in Crohn's disease; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Humira (adalimumab)

Snippet

Sponsor: Abbott | Conditions: Crohn's Disease | Phase 3 | Status: COMPLETED